*Beijing You'an Hospital, Capital Medical University, Beijing, China †MRC Clinical Trials Unit, London, United Kingdom ‡University College London Medical School, London, United Kingdom §Tartu Ülikool, Tartu, Estonia ‖The Kirby Institute, University of New South Wales, Darlinghurst, Australia ¶University of Oxford, Oxford, United Kingdom.
J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a.
Little is known about the natural history of the HIV infection in men who have sex with men (MSM) in China.
We compared changes in CD4+ T-cell count and HIV-RNA following seroconversion before starting antiretroviral therapy between MSM in China and in resource-rich countries using data from the Beijing PRIMO cohort and Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE), respectively. Linear mixed models were used to compare rates of CD4 decline (cubic root scale) and changes in HIV-RNA (log10 scale) in the first 3 years following seroconversion.
For 131 PRIMO and 3171 CASCADE MSM infected in 2001-2010, estimated CD4+ T-cell count at seroconversion was lower in PRIMO (504 cells/mm3; 95% confidence interval: 463 to 547) compared with CASCADE (554 cells/mm3; 544 to 564). CD4 decline was significantly faster for PRIMO men [-0.59 (-0.72 to -0.47) and - 0.41 (-0.44 to -0.38) cubic root of CD4 count/year for PRIMO and CASCADE, respectively], even after restricting to subtype B (P = 0.01). HIV-RNA at seroconversion was lower in PRIMO compared with CASCADE MSM [difference 0.425 log10/mL (0.249 to 0.603), P < 0.001]. After the first year of seroconversion, PRIMO MSM experienced a faster increase in HIV-RNA [0.830 log10/mL per year; (0.484 to 1.168)] compared with CASCADE MSM [0.018 (-0.035 to 0.067)] (P < 0.001).
CD4 decline and HIV-RNA increase are faster between MSM in China compared with MSM from resource-rich settings. Whether this is due to differences in host immunity or viral characteristics requires further exploration.
在中国,男男性行为者(MSM)中 HIV 感染的自然史知之甚少。
我们分别使用北京 PRIMO 队列和 Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE)的数据,比较了中国和资源丰富国家的 MSM 在开始抗逆转录病毒治疗前血清转换后 CD4+T 细胞计数和 HIV-RNA 的变化。使用线性混合模型比较了血清转换后前 3 年内 CD4 下降(立方根标度)和 HIV-RNA 变化(对数标度)的速率。
在 2001-2010 年感染的 131 名 PRIMO 和 3171 名 CASCADE MSM 中,PRIMO 的 CD4+T 细胞计数在血清转换时较低(504 个细胞/mm3;95%置信区间:463 至 547),而 CASCADE 则较高(554 个细胞/mm3;544 至 564)。PRIMO 男性的 CD4 下降速度明显较快[-0.59(-0.72 至 -0.47)和 -0.41(-0.44 至 -0.38)个 CD4 计数/年,分别为 PRIMO 和 CASCADE],即使限制为 B 亚型(P = 0.01)也是如此。与 CASCADE MSM 相比,PRIMO 的血清转换时 HIV-RNA 较低[差异 0.425 log10/mL(0.249 至 0.603),P<0.001]。在血清转换后的第一年,PRIMO MSM 的 HIV-RNA 增加速度较快[每年 0.830 log10/mL;(0.484 至 1.168)],而 CASCADE MSM 则较慢[每年 0.018(-0.035 至 0.067)](P<0.001)。
与资源丰富地区的 MSM 相比,中国 MSM 的 CD4 下降和 HIV-RNA 增加速度更快。这是否是由于宿主免疫或病毒特征的差异所致,需要进一步探讨。